AU2018380132B2 - Tubulin inhibitors - Google Patents

Tubulin inhibitors Download PDF

Info

Publication number
AU2018380132B2
AU2018380132B2 AU2018380132A AU2018380132A AU2018380132B2 AU 2018380132 B2 AU2018380132 B2 AU 2018380132B2 AU 2018380132 A AU2018380132 A AU 2018380132A AU 2018380132 A AU2018380132 A AU 2018380132A AU 2018380132 B2 AU2018380132 B2 AU 2018380132B2
Authority
AU
Australia
Prior art keywords
formula
alkyl
compound
halogen
nrrd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018380132A
Other languages
English (en)
Other versions
AU2018380132A1 (en
AU2018380132A8 (en
Inventor
Jessica CRISP
Tom Lin
Jason OLEJNICZAK
Richard Truong
Cheng-Chi Irene Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lin Bio Inc
Original Assignee
Lin Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lin Bio Inc filed Critical Lin Bio Inc
Publication of AU2018380132A1 publication Critical patent/AU2018380132A1/en
Publication of AU2018380132A8 publication Critical patent/AU2018380132A8/en
Assigned to Lin Bioscience, Inc. reassignment Lin Bioscience, Inc. Request for Assignment Assignors: Lin Bioscience, Pty Ltd.
Application granted granted Critical
Publication of AU2018380132B2 publication Critical patent/AU2018380132B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Epoxy Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018380132A 2017-12-06 2018-12-05 Tubulin inhibitors Active AU2018380132B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762595530P 2017-12-06 2017-12-06
US62/595,530 2017-12-06
PCT/US2018/064114 WO2019113242A1 (en) 2017-12-06 2018-12-05 Tubulin inhibitors

Publications (3)

Publication Number Publication Date
AU2018380132A1 AU2018380132A1 (en) 2020-06-18
AU2018380132A8 AU2018380132A8 (en) 2020-07-09
AU2018380132B2 true AU2018380132B2 (en) 2023-11-09

Family

ID=66658388

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018380132A Active AU2018380132B2 (en) 2017-12-06 2018-12-05 Tubulin inhibitors

Country Status (8)

Country Link
US (3) US11040945B2 (enExample)
EP (1) EP3720436A4 (enExample)
JP (1) JP7319977B2 (enExample)
KR (1) KR20200104873A (enExample)
CN (1) CN111727042A (enExample)
AU (1) AU2018380132B2 (enExample)
TW (1) TWI828644B (enExample)
WO (1) WO2019113242A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019200683B2 (en) * 2018-02-01 2024-05-30 The University Of Sydney Anti-cancer compounds
JP7184383B2 (ja) * 2018-02-01 2022-12-06 ザ・ユニバーシティ・オブ・シドニー 抗癌性化合物
JP7594787B2 (ja) 2018-12-07 2024-12-05 ユニバーシティ オブ メリーランド、ボルチモア 非ＡＴＰ／触媒部位ｐ３８マイトジェン活性化プロテインキナーゼ阻害剤
CN114206339A (zh) 2019-07-31 2022-03-18 阿克拉瑞斯治疗股份有限公司 氘化mk2途径抑制剂及其使用方法
US20210147441A1 (en) * 2019-09-26 2021-05-20 Agency For Science, Technology And Research (A*Star) Therapeutic compounds and methods of use thereof
KR20220119653A (ko) 2019-12-20 2022-08-30 테나야 테라퓨틱스, 인코포레이티드 플루오로알킬-옥사디아졸 및 이의 용도
IL296054A (en) 2020-03-27 2022-10-01 Aclaris Therapeutics Inc Oral compositions of mk2 pathway inhibitor for treatment of immune conditions
KR102844239B1 (ko) * 2020-11-10 2025-08-08 가천대학교 산학협력단 신규한 카바졸 유도체 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
NZ804686A (en) * 2021-03-23 2026-03-27 Gen1E Lifesciences Inc Substituted naphthyl p38alpha mitogen-activated protein kinase inhibitors
US20240252502A1 (en) 2021-05-04 2024-08-01 Tenaya Therapeutics, Inc. Hdac6 inhibitors for treatment of metabolic disease and hfpef

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016119017A1 (en) * 2015-01-30 2016-08-04 The University Of Sydney Anti-cancer compounds

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2205732A1 (de) 1972-02-08 1973-08-16 Thomae Gmbh Dr K Neue 4-(4-biphenylyl)-butensaeurederivate
IT1044222B (it) 1972-05-23 1980-03-20 Zambeletti Spa L Bifenilil alcanoilaminopiridine ad attivita anti infiammatoria di lunga durata
AT336594B (de) 1973-08-14 1977-05-10 Thomae Gmbh Dr K Verfahren zur herstellung neuer 3-(4- biphenylyl)-buttersaureamiden
US5196543A (en) 1989-10-17 1993-03-23 Delalande S.A. 3-aryloxazolidinone derivatives, process for their preparation and their use in therapy
EP0533753A1 (en) 1990-06-14 1993-03-31 Washington University Rna hydrolysis/cleavage
JP2969618B2 (ja) * 1995-06-27 1999-11-02 田辺製薬株式会社 ピリダジノン誘導体及びその製法
US5756507A (en) 1995-12-14 1998-05-26 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
JP3060454B2 (ja) * 1996-12-26 2000-07-10 田辺製薬株式会社 医薬組成物
US6114365A (en) 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
MXPA02001498A (es) 1999-08-12 2003-07-21 Pharmacia & Italia S P A Derivados de 3(5)-amino-pirazol, procedimiento para la preparacion de los mismos y usos como agentes antitumorales.
ES2193839B1 (es) 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
PT1689715E (pt) 2003-12-03 2011-05-16 Ym Biosciences Australia Pty Inibidores da tubulina
ATE531705T1 (de) 2004-05-18 2011-11-15 Schering Corp Substituierte 2-chinolyloxazole geeignet als pde4 inhibitoren
AU2005310238A1 (en) 2004-10-29 2006-06-08 Merck Sharp & Dohme Corp. N-(pyridin-3-yl)-2-phenylbutanamides as androgen receptor modulators
DE602006007558D1 (de) * 2005-03-15 2009-08-13 4Sc Ag N-sulfonylpyrrole und ihre verwendung als histondeacetylaseinhibitoren
WO2007123953A2 (en) 2006-04-19 2007-11-01 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
ES2431466T3 (es) 2006-06-30 2013-11-26 Sunesis Pharmaceuticals, Inc. Inhibidores de piridinonil pdk1
JP2009185010A (ja) 2008-02-08 2009-08-20 Taisho Pharmaceutical Co Ltd グリシントランスポーター阻害剤を含有する医薬
FR2933700B1 (fr) * 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
KR20120059558A (ko) 2009-08-19 2012-06-08 암비트 바이오사이언시즈 코포레이션 바이아릴 화합물 및 이의 사용 방법
FR2952934B1 (fr) * 2009-11-23 2012-06-22 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
EA201201274A1 (ru) * 2010-03-10 2013-04-30 Инджениум Фармасьютиклз Гмбх Ингибиторы протеинкиназ
RU2576662C2 (ru) 2010-03-18 2016-03-10 Энститю Пастер Корея Противоинфекционные соединения
EP2729146B1 (en) 2011-07-08 2017-03-08 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for treatment of liver cancer
US20130267712A1 (en) 2012-04-02 2013-10-10 Board Of Trustees Of Northern Illinois University Aromatic ketone synthesis with amide reagents and related reactions
CN105473559B (zh) 2013-03-15 2019-05-10 南洋理工大学 用于化学转化的羰基β-碳的活化
AR098475A1 (es) 2013-11-26 2016-06-01 Bayer Cropscience Ag Compuestos pesticidas y usos
WO2016067009A1 (en) 2014-10-28 2016-05-06 Redx Pharma Plc Compounds with activity against bacteria and mycobacteria
DK3302448T3 (da) 2015-06-04 2024-02-05 Aurigene Oncology Ltd Erstattede heterocyclylafledninger som cdk-inhibitore

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016119017A1 (en) * 2015-01-30 2016-08-04 The University Of Sydney Anti-cancer compounds

Also Published As

Publication number Publication date
EP3720436A1 (en) 2020-10-14
AU2018380132A1 (en) 2020-06-18
KR20200104873A (ko) 2020-09-04
AU2018380132A8 (en) 2020-07-09
CN111727042A (zh) 2020-09-29
US20220089539A1 (en) 2022-03-24
US20250188035A1 (en) 2025-06-12
US11040945B2 (en) 2021-06-22
WO2019113242A1 (en) 2019-06-13
TW201930266A (zh) 2019-08-01
JP7319977B2 (ja) 2023-08-02
US12247010B2 (en) 2025-03-11
TWI828644B (zh) 2024-01-11
EP3720436A4 (en) 2021-06-02
JP2021508318A (ja) 2021-03-04
US20190169127A1 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
US12247010B2 (en) Tubulin inhibitors
CA2915561C (en) Novel substituted bicyclic compounds as bromodomain inhibitors
CA3219348A1 (en) Checkpoint kinase 1 (chk1) inhibitors and uses thereof
CA2710043C (en) Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
EP2476679B1 (en) Substituted triazoles useful as AXL inhibitors
CA2710046C (en) N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as axl inhibitors
JP6663866B2 (ja) リジン特異的なデメチラーゼ−１の阻害剤
JP2017501234A (ja) グルタミナーゼの新規阻害剤
CA3190653A1 (en) Bicyclic bromodomain inhibitors
WO2020227020A1 (en) Inhibitors of raf kinases
KR20250012101A (ko) Parg의 억제제
WO2022081469A1 (en) Inhibitors of raf kinases
US11780862B2 (en) Inhibitors of MEK kinase
CA3195859A1 (en) Inhaled formulations of pgdh inhibitors and methods of use thereof
AU2022406595B2 (en) Anti-apoptotic protein bcl-2 inhibitor, pharmaceutical composition and uses thereof
WO2025054260A1 (en) Inhibitors of mek kinase
WO2026060099A1 (en) Selective pi3k inhibitors
CN118047757A (zh) 吡啶氮氧化物类衍生物及其药物组合物、制备方法和用途
CN120136783A (zh) 吡啶氮氧化物类衍生物及其药物组合物、制备方法和用途

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 34 , NO 24 , PAGE(S) 3342 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME LIN BIOSCIENCE, LLC, APPLICATION NO. 2018380132, UNDER INID (71) CORRECT THE APPLICANT NAME TO LIN BIOSCIENCE, PTY LTD.

PC1 Assignment before grant (sect. 113)

Owner name: LIN BIOSCIENCE, INC.

Free format text: FORMER APPLICANT(S): LIN BIOSCIENCE, PTY LTD.

FGA Letters patent sealed or granted (standard patent)